|Day Low/High||5.90 / 6.02|
|52 Wk Low/High||4.98 / 18.83|
The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 4,046,337 share increase in total short interest for Amicus Therapeutics Inc , to 32,785,226, an increase of 14.08% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Investors in Amicus Therapeutics Inc saw new options become available this week, for the February 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new February 17th contracts and identified the following call contract of particular interest.
Amicus Therapeutics, Nantkwest and Organovo are among the premarket biotech movers on Tuesday.
Investors in Amicus Therapeutics Inc saw new options become available today, for the October 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 276 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Insiders at these companies -- including Occidental Petroleum and Six Flags Entertainment -- have been scooping up shares of their own stock lately.
Insiders have an edge in this complex sector, so it's worth checking them out.
Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.
Levi & Korsinsky announces it has commenced an investigation of Amicus Therapeutics, Inc.
In trading on Tuesday, shares of Amicus Therapeutics Inc crossed below their 200 day moving average of $7.13, changing hands as low as $6.30 per share. Amicus Therapeutics Inc shares are currently trading off about 22.2% on the day.
Futures remain soft, but analysts believe rally still has steam.
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.